News | May 6, 2019

Hospital Auxilio Mutuo In Puerto Rico Advances Its Lab Testing For Transplant Patients With The Atellica Solution

MALVERN, PA.--(BUSINESS WIRE)--

Siemens Healthineers announced today that Hospital Auxilio Mutuo in Puerto Rico has become the first hospital on the island and the first transplant center in the world to advance its laboratory testing with the Atellica® Solution.1 The immunoassay and clinical chemistry analyzers from Siemens Healthineers offer laboratories state-of-the-art testing capabilities and a comprehensive test menu to help improve patient outcomes.

When preparing a patient for a transplant, a variety of testing needs to be conducted to help determine if a patient is healthy enough for surgery. Early identification of antibodies that may cause a possible graft rejection and also the ability to detect a patient’s viral load are important testing that needs to occur in the pre- and post- transplant phases to monitor the possibility of infection. In the post-transplant period, among the most important test results for clinicians are donor-specific antibodies which could indicate a donor is rejecting the transplant. This testing needs to deliver results quickly and efficiently.

“We are in a new era in the laboratory,” said Francheska Rivera, Laboratory Supervisor at Hospital Auxilio Mutuo. “Our main goal is to improve the laboratory with state-of-the-art instrumentation to ensure the highest standards as much as possible. The focus and vision is quality patient care with the best resources available in the market, and best-in-class technology and service that meets our goals. The Atellica Solution allows, among other things, us to consolidate four instruments into one by integrating the immunoassay and clinical chemistry analyzers, to improve efficiency, and to maximize our staff.”

Hospital Auxilio Mutuo in Puerto Rico runs more than 70,000 tests on a monthly basis. The Atellica Solution will enable the laboratory to consolidate several instruments for improved efficiency in the lab, while growing its testing capacity and menu to better serve its patients.

“Specialty facilities across North America are entrusting the Atellica Solution from Siemens Healthineers with the testing needs of their most fragile patients,” said Andy Olen, Senior Vice President, Diagnostics, North America, Siemens Healthineers. “With its comprehensive menu and unique features and benefits for quality control, the Atellica Solution is proving to be an offering to help laboratories across the country to improve patient outcomes, optimize their workflow, grow their testing menu, or expand their capabilities.”

For further information on the Atellica Solution, please visit www.siemens-healthineers.us/atellicasolution

1 Product availability varies by country.

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

Copyright Business Wire 2019